24/7 Market News Snapshot 26 September, 2025 – Fractyl Health, Inc. Common Stock (NASDAQ:GUTS)

September 26, 2025

DENVER, Colo., 26 September, 2025 (www.247marketnews.com) – (Nasdaq:GUTS) are discussed in this article.
Fractyl Health, Inc. (Nasdaq:GUTS), a leader in metabolic therapeutics, has garnered significant market attention following a noteworthy surge in pre-market trading, with shares climbing 22.48% to $1.237. This increase comes alongside a remarkable trading volume of 6.16 million shares, reflecting strong investor confidence in the company’s innovative health solutions. The positive momentum is viewed as an indication of potential future growth, marking GUTS as a stock to watch in the healthcare sector.

In a strategic financial maneuver, Fractyl has recently priced an underwritten offering of 60 million shares of its common stock at $1.00 per share, aiming to raise approximately $60 million in gross proceeds, excluding underwriting discounts and expenses. The closing of this offering is expected to occur on or around September 29, 2025, subject to customary closing conditions. BofA Securities and Evercore ISI have been appointed as joint book-running managers, while Ladenburg Thalmann serves as the lead manager.

Fractyl Health is committed to transforming the treatment of obesity and type 2 diabetes (T2D) by focusing on underlying causes rather than merely addressing symptoms. With chronic conditions still presenting serious health challenges worldwide, Fractyl’s innovative approach seeks to deliver sustainable, disease-modifying therapies. The company supports its mission with a robust portfolio of intellectual property, encompassing 33 granted U.S. patents and around 40 pending applications, alongside additional international patents.

Earlier this year, Fractyl filed a shelf registration statement with the Securities and Exchange Commission (SEC), subsequently declared effective. A final prospectus supplement will be available through the SEC’s website, providing more details on the offering. This financial development marks a significant milestone in Fractyl’s ongoing efforts to tackle the increasing public health crisis posed by metabolic diseases, reinforcing its position in advancing effective therapeutic solutions.

Related news for (GUTS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.